Clarivate faces persistent revenue contraction, with 2026Q2 revenue down 5.5% year-over-year to $587.3M, and recurring operating losses, including a -$200.2M operating income in the same quarter. However, the company generates robust operating cash flow despit...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.19+4.6% vs $0.18 | $587M-0.4% vs $590M |
Q2 2026 Apr 29, 2026 | $0.18+28.6% vs $0.14 | $586M+2.8% vs $569M |
Q1 2026 Feb 24, 2026 | $0.20+25.0% vs $0.16 | $617M+2.0% vs $605M |
Q4 2025 Oct 29, 2025 | $0.18+12.5% vs $0.16 | $623M+3.0% vs $605M |
Shares of Clarivate PLC (NYSE: CLVT - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced a cash tender offer (the "Offer") to purchase the outstanding notes described below, upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase").
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific BreakthroughsPR NewswireLONDON, Sept. 17, 202622 researchers honored for Nobel-c
22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the Citation Laureates 2026, a distinguished group of 22 researchers whose work is of Nobel class.
Benchmark CLVT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Clarivate Plc (CLVT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.83 | $1.17B | -6.10 | -3.97% | -8.19% | -4.03% | — | |
| $171.80 | $22.36B | 26.47 | 6.63% | 28.24% | — | — | |
| $555.70 | $40.4B | 35.71 | 9.51% | 40.74% | — | — | |
| $98.45 | $42.98B | 28.96 | 3% | 21.22% | 14.26% | — | |
| $8.42 | $2.83B | 20.05 | -7.55% | 9.15% | — | — | |
| $406.50 | $119.84B | 27.73 | 8.18% | 30.53% | 13.43% | — |
Clarivate Plc (CLVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Clarivate Plc (CLVT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 29, 2026·SEC
Jul 6, 2026·SEC
Get notified when CLVT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Clarivate Plc (CLVT) stock FAQ — growth, dividends, profitability & financials explained
Clarivate Plc (CLVT) reported $2.41B in revenue for fiscal year 2025. This represents a 163% increase from $917.6M in 2017.
Clarivate Plc (CLVT) saw revenue decline by 4.0% over the past year.
Clarivate Plc (CLVT) reported a net loss of $334.0M for fiscal year 2025.
Clarivate Plc (CLVT) has a return on equity (ROE) of -4.0%. Negative ROE indicates the company is unprofitable.
Clarivate Plc (CLVT) generated $582.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
